- Home
- NKSH vs OBIO Comparison
NKSH vs OBIO Comparison
Compare NKSH & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NKSH | OBIO |
|---|---|---|
| Founded | 1891 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 233.8M | 240.7M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NKSH | OBIO |
|---|---|---|
| Price | $36.55 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.25 |
| AVG Volume (30 Days) | 25.2K | ★ 497.3K |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | ★ 100.81 | 33.13 |
| EPS | ★ 0.78 | N/A |
| Revenue | $8,176,000.00 | ★ $33,482,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $12.43 |
| P/E Ratio | $46.86 | ★ N/A |
| Revenue Growth | 9.39 | ★ 1169.22 |
| 52 Week Low | $27.00 | $2.20 |
| 52 Week High | $40.00 | $5.42 |
Technical Indicators
Market Signals| Indicator | NKSH | OBIO |
|---|---|---|
| Relative Strength Index (RSI) | 53.26 | 52.38 |
| Support Level | $35.02 | $3.96 |
| Resistance Level | $38.04 | $4.82 |
| Average True Range (ATR) | 1.21 | 0.27 |
| MACD | 0.11 | 0.04 |
| Stochastic Oscillator | 57.10 | 36.53 |
Price Performance
Historical ComparisonAbout NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural loans, commercial real estate, construction loans for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary. The company earns its revenue from interest and fees on loans, non-interest income, and investments.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.